RPL30P6

Across TCGA pan-cancer cohorts, RPL30P6 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated RPL30P6 data layer.

The strongest signal is observed in uveal melanoma (UVM), where higher RPL30P6 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL30P6 expression acts as an unfavorable survival marker, although some lineages such as ESCA and ACC show a favorable association.

UVM, BLCA, and PAAD are the cancer types where RPL30P6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	DFS	Tertile	All	0.032	0.762	<.001	90	view →
BLCA	DFS	Tertile	III,IV	0.281	0.555	.002	36	view →
PAAD	OS	Tertile	All	0.100	0.590	<.001	36	view →
SKCM	OS	Tertile	III,IV	0.179	0.801	<.001	36	view →
STAD	OS	Tertile	III,IV	0.156	0.553	<.001	36	view →
HNSC	OS	Tertile	II,III,IV	0.457	0.726	.017	27	view →
ESCA	OS	Tertile	III,IV	0.802	0.363	.010	18	view →
LUAD	OS	Tertile	III,IV	0.255	0.666	.018	18	view →
ACC	DFS	Tertile	II,III,IV	1.000	0.333	.046	6	view →
PRAD	OS	Tertile	All	0.909	0.990	.020	6	view →
THCA	OS	Tertile	II,III,IV	0.851	0.979	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

RPL30P6–UVM (DFS)

Open the UVM breakdown →